7.7709

2.75% -0.2291

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $7.7709, with a volume of 59,745. It is down -2.75% in the last 24 hours and down -5.93% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$8.00

Open:

$7.98

24h Volume:

59,745

Relative Volume:

0.07

Market Cap:

$564.66M

Revenue:

Net Income/Loss:

$-119.87M

P/E Ratio:

-4.2933

EPS:

-1.81

Net Cash Flow:

$-109.90M

1W Performance:

-0.89%

1M Performance:

-5.93%

6M Performance:

-21.33%

1Y Performance:

-48.92%

1-Day Range:

$7.74

$8.08

1-Week Range:

$7.22

$8.11

52-Week Range:

$6.33

$15.40

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

115

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	7.785	564.66M	0	-119.87M	-109.90M	-1.81
VRTX Vertex Pharmaceuticals Inc	499.31	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.02	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.08	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.73	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.72	26.76B	3.32B	-860.46M	-1.04B	-8.32

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

Mar 12, 2025

(ORIC) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 12, 2025

Mar 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 07, 2025

ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan

Mar 07, 2025

Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 07, 2025

Mar 06, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Mar 06, 2025

ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat

Mar 06, 2025

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World

Mar 06, 2025

Mar 05, 2025

ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks

Mar 05, 2025

Mar 04, 2025

Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat

Mar 04, 2025

Mar 03, 2025

ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World

Mar 03, 2025

Mar 02, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat

Mar 02, 2025

Mar 01, 2025

(ORIC) Investment Analysis and Advice - Stock Traders Daily

Mar 01, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World

Mar 01, 2025

ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025

JPMorgan Chase & Co. Increases ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $22.00 - MarketBeat

Mar 01, 2025

Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World

Mar 01, 2025

Feb 28, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World

Feb 28, 2025

Feb 26, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat

Feb 26, 2025

Feb 25, 2025

Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks

Feb 25, 2025

ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire

Feb 25, 2025

Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan

Feb 25, 2025

Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat

Feb 25, 2025

Feb 24, 2025

HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Feb 24, 2025

Feb 23, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat

Feb 23, 2025

HC Wainwright Reaffirms Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World

Feb 23, 2025

Feb 22, 2025

Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals - Defense World

Feb 22, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 22, 2025

Feb 20, 2025